NCT05689034View on ClinicalTrials.gov

Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

1,096

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
COVID-19 Respiratory Infection
Interventions
DRUG

Azvudine

Azvudine po. 5mg daily for 7 days

DRUG

Placebo

Placebo po. 5 tablets daily for 7 days

Trial Locations (1)

100730

RECRUITING

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER